Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Cancer Research / Analyser for validering av histone…
JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content.

JoVE Journal Cancer Research
Analyser for validering av histone acetyltransferasehemmere
A Unified Methodological Framework for Vestibular Schwannoma Research
Journal (Cancer Research)
A Unified Methodological Framework for Vestibular Schwannoma Research
Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples
Journal (Cancer Research)
Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples
 
Click here for the English version

Analyser for validering av histone acetyltransferasehemmere

Article DOI: 10.3791/61289-v • 09:11 min • August 6th, 2020
August 6th, 2020 •
1, 1
1Department of Anatomy and Cell Biology, and UF Health Cancer Center, University of Florida College of Medicine

Chapters

Summary
Automatic Translation

Please note that all translations are automatically generated.

Click here for the English version.

Hemmere av histone acetyltransferaser (HATs, også kjent som lysin acetyltransferaser), som CBP/p300, er potensielle terapeutiske midler for behandling av kreft. Imidlertid er det nødvendig med strenge metoder for å validere disse hemmerne. Tre in vitro metoder for validering inkluderer HAT-analyser med rekombinante acetyltransferaser, immunoblotting for histone acetylering i cellekultur, og ChIP-qPCR.

Tags

Kreftforskning utgave 162 lysinacetyltransferaser KATs CBP/p300 histone acetyltransferasehemmere screeningmetoder histoneseedylering epigenetikk kreft genregulering
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter